Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
Randomized controlled trial · J Clin Endocrinol Metab · 2013. Source record refreshed; an explanation has not been reviewed.
About this paper
This page identifies the publication and its source. A checked explanation of its findings is not yet available.
Reading this record
Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.
Publication details
Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
Catalano A, Morabito N, Basile G et al.
J Clin Endocrinol Metab · 2013
- PubMed ID
- 23596142
- Record checked
A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.
Keep your place in the research.
Save this source or mark it as read.